Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 4Neoplasm Metastasis 4Urogenital Neoplasms 2Prostatic Neoplasms 2Lung Neoplasms 2Solitary Fibrous Tumors 1Solid Tumors Harboring NTRK Fusion 1Small Cell Lung Carcinoma 1Sarcoma 1Respiratory Syncytial Virus Infections 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Osteosarcoma 1Neuroblastoma 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Kidney Neoplasms 1Granuloma, Plasma Cell 1Glioma 1Glioblastoma 1Genital Neoplasms, Male 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

remdesivir 1Suspensions 1Specimen Handling 1Ribavirin 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Respiratory Syncytial Virus Infections × Suspensions × Clear all
NCT06597916 2024-11-27

RSV Vaccination in Immunocompromised Patients.

Medical University of Vienna

Phase 2 Recruiting
200 enrolled

Respiratory Syncytial Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡